ReviewAging and disease2025
Immunosenescence: Shaping the Hematological Narrative in the Era of Aging.
Review in Aging and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aging has emerged as a critical focus in understanding human diseases. Among many factors in aging, immunosenescence stands out as a significant focus. Immunosenescence is the process of physiological and functional deterioration of the immune system, which consists of organs, cells, immune components and regulatory networks. In hematologic diseases, immunosenescence could affect the bone marrow (BM) microenvironment, resulting in reduced function of hematopoietic stem and progenitor cells, and interfering with normal hematopoiesis. However, how the nature and function of immune cells change during immunosenescence and the effects have not yet been summarized and explored. Therefore, this review reveals the dual role of immunosenescence in increased disease risk and reduced therapeutic efficacy by providing an overview of the characteristics of immunosenescence, the interaction with the mechanisms of development of hematologic diseases, and the impact of immunosenescence on the function of individual immune cells during the diseases. It includes separate descriptions of various immune cells (innate and adaptive immune response cells) involved in immunosenescence, which covers changes in their cell numbers, subpopulations, receptors, cytokine levels, and other aspects. Additionally, it provides an in-depth analysis of how these changes influence the progression of hematologic diseases (both neoplastic and non-neoplastic hematological diseases). Additionally, we explore the impact of senescence on therapeutic strategies and propose treatment programs for elderly patients. With this review, we endeavor to further disclose the mystery of how immunosenescence impacts the onset and progression of hematologic disorders, aiming to offer a scientific footing for devising novel therapeutic approaches for elderly patients and to enhance their prognosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.